The primary therapeutic role of Kast is to provide essential supportive management for conditions involving airway inflammation, thereby helping to ease the overall symptom burden and supporting patient comfort across several key respiratory domains. The medication is commonly used across conditions presenting with episodic or fluctuating symptom patterns.

The primary uses for Kast are for the prophylaxis and chronic treatment of asthma, for the acute prevention of exercise-induced bronchoconstriction (EIB), and for the symptomatic relief of Seasonal and Perennial Allergic Rhinitis.

Chronic Maintenance for Asthma Symptoms

Kast is generally used for the prophylaxis and chronic treatment of asthma, and is commonly used for managing conditions characterized by periods of heightened symptoms. It is applied to address symptom clusters that may become intense or disruptive, such as recurrent wheezing, chest tightness, and persistent coughing. This supports the patient during difficult episodes by helping to maintain a sense of stability when symptoms are more noticeable.

“The medication may assist with managing symptoms related to inflammatory or irritative states.”

Relief of Seasonal and Year-Round Allergic Rhinitis

The medication is relevant in contexts involving heightened systemic burden due to allergies, including both seasonal (hay fever) and perennial (year-round) rhinitis. It is relevant for easing symptoms that may become disruptive like disruptive sneezing, excessive nasal congestion, and rhinorrhea (runny nose). This provides supportive relief when symptoms interfere with routine activities, helping to improve day-to-day comfort.

---

Quick Fact: Supports Management of Nasal Congestion Kast is relevant for easing symptoms related to heightened physiological activity, helping to address the symptoms of a stuffy nose associated with allergic rhinitis.

Preventative Support for Exercise-Induced Breathing

Kast may be part of symptomatic management applied in scenarios where additional management of discomfort is required, specifically for the acute prevention of EIB. Relevant in contexts involving heightened systemic burden, such as when engaging in physical activity, it helps maintain a sense of stability when symptoms are more noticeable, supporting patients during difficult episodes.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Kast? Official Regulatory Information

The eligibility profile for Kast (Montelukast sodium) is strictly defined by regulatory documents, specifying who is permitted to use the medicine and under what conditions.

Contraindications (Must Not Use)

Kast is contraindicated in patients with a known history of hypersensitivity to Montelukast sodium or any component of the formulation. Additionally, patients with Phenylketonuria (PKU) are contraindicated from using the chewable tablet formulation, as it contains phenylalanine.

Age-Related Eligibility Rules

Indication	Minimum Established Age for Use
Perennial Allergic Rhinitis (PAR)	ge 6 months of age
Asthma (Chronic Treatment)	ge 12 months of age
Exercise-Induced Bronchoconstriction (EIB) Prevention	ge 6 years of age

Restrictions and Limitations of Use

• Acute Asthma: Kast is not indicated for the reversal of bronchospasm during an acute asthma attack or status asthmaticus. All patients must have appropriate rescue medication available.
• Allergic Rhinitis: For the treatment of allergic rhinitis, regulatory agencies advise that use be reserved for patients who have an inadequate response or intolerance to alternative therapies.
• Organ Impairment: No dosage adjustment is recommended for patients with renal impairment or mild-to-moderate hepatic impairment; however, use in severe hepatic insufficiency has not been fully assessed.
• Pregnancy/Lactation: Available data have not established a drug-associated risk of major congenital disabilities during pregnancy, and only low levels appear in breast milk, with data not suggesting a significant risk to the infant. Use is based on clinical need.

Interactions with Other Medicines and Products

The official interaction profile for Kast (Montelukast) is primarily defined by its clearance through the CYP3A4, CYP2C8, and CYP2C9 metabolic pathways. Montelukast is documented as a substrate for these enzymes but is not classified as an inhibitor of major CYP isozymes at therapeutic doses.

Documented Interaction Outcomes

Substance Category	Interaction Effect	Classification
CYP Inducers (e.g., Phenobarbital, Rifampicin)	Decreases Montelukast systemic exposure (AUC reduced by sim 40%)	Pharmacokinetic
CYP Inhibitors (e.g., Gemfibrozil)	Increases Montelukast systemic exposure (up to 4.4-fold)	Pharmacokinetic
Beta-Agonists	Bronchodilation effect is officially documented as additive	Pharmacodynamic

Co-administration with other products containing Montelukast is an officially contraindicated combination due to the risk of therapeutic duplication. The pharmacokinetics of Montelukast are not significantly affected by Warfarin, Digoxin, or Theophylline. For the oral granule form, a high-fat meal is documented to reduce the maximum plasma concentration ( Cmax) by 35%. Furthermore, the official label recommends caution when co-administering CYP inducers in children. Mandatory timing rules require oral granules to be administered within 15 minutes of opening the packet.

Kast works by acting as a selective and competitive antagonist at the Cysteinyl Leukotriene Receptor 1 (CysLT1), which is expressed on airway smooth muscle and various inflammatory cells. This mechanism engages a core system where mediators, primarily Leukotriene D4 (LTD4), normally bind to signal bronchoconstriction and inflammation. By physically blocking this receptor, the drug prevents LTD4 from initiating its signaling sequence.

This blockade modifies the early molecular steps that shape systemic physiological outcomes. By inhibiting the leukotriene-mediated cascade, the drug directly counteracts the signals that cause airway muscles to tighten and local blood vessels to become overly permeable. This action results in a physiological consequence of bronchodilation and reduced local vascular permeability (edema) within the airway wall.

Furthermore, Montelukast disrupts the chemotactic signaling that attracts immune cells like eosinophils into the airways, thereby limiting the buildup of cellular inflammation. This overall mechanism results in a decrease in airway hyperresponsiveness caused by leukotriene signaling.

How to Use Kast: Official Administration Guidelines

Kast (montelukast sodium) is administered solely by the oral route. The standard regimen for most indications is once daily, and treatment is typically long-term and continuous. Patients should continue taking the medicine even during symptom-free periods.

---

Official Dosing and Administration

The dosage strength and formulation are dependent on the patient's age and the condition being managed. Labeled doses are fixed and do not typically require adjustment in patients with mild-to-moderate hepatic impairment or renal impairment.

Age Group	Condition	Standard Daily Dose	Timing/Form Constraints
Adults (15+ years)	Chronic Asthma / Rhinitis	10 mg (film-coated tablet)	Once daily, preferably in the evening.
Pediatric (6–14 years)	Chronic Asthma / Rhinitis	5 mg (chewable tablet)	Once daily, in the evening.
Pediatric (2–5 years)	Chronic Asthma / Rhinitis	4 mg (chewable tablet or granule)	Once daily, in the evening.

---

Administration Context and Special Handling

For chronic asthma management, the dose should be taken in the evening to align with nocturnal symptom patterns. The 10 mg film-coated tablet can be taken with or without food. For the acute prevention of Exercise-Induced Bronchoconstriction (EIB), a single 10 mg dose (for adults) must be taken at least two hours prior to exercise; this is not a supplementary dose and should not be taken in addition to the regular daily dose.

Oral granules require specific handling: they must be administered within 15 minutes of opening the sachet. They can be poured directly onto the tongue or mixed with a spoonful of soft, cold or room-temperature food, such as applesauce, or a small volume of formula or breast milk; the mixture must not be stored for later use.

Research Evidence Overview

This section summarizes the official clinical evaluation for Kast (montelukast), detailing the types of studies performed, the patient populations examined, and the primary outcomes researchers tracked, as reported in authoritative scientific and regulatory sources. Studies monitored outcomes reflecting daily functioning and activity level, and the evidence contributes to the broader evidence landscape by describing group patterns observed, but this research does not determine whether an individual will respond similarly.

---

Evidence for Chronic Maintenance Treatment of Asthma

The structure of the evidence was evaluated in research exploring the long-term management of asthma, focusing on randomized controlled trials (RCTs) across adults and children down to 6 months of age. Research examined outcomes related to systemic or functional imbalance, such as lung function ( FEV1), and patient-reported outcomes describing perceived discomfort. When the medicine was observed in studies as an add-on to standard controllers, research explored whether this combination was associated with measured changes in control scores.

---

Evidence for Acute Prevention of Exercise-Induced Bronchoconstriction (EIB)

This part outlines the specialized studies that assessed the patterns observed regarding breathing changes following exercise in patients aged 6 years and older. The main outcomes tracked the maximum drop in measured lung function ( FEV1) after a controlled exercise challenge. Findings describe patterns where the fall in lung function after exercise was reported to be smaller in the group receiving the medicine compared to the placebo group.

---

Evidence for Symptomatic Relief of Allergic Rhinitis

The clinical evaluation for seasonal and perennial allergic rhinitis relies on short-term RCTs comparing the medicine to placebo. Researchers examined patient-reported outcomes describing perceived discomfort using composite scores, such as the Total Nasal Symptom Score (TNSS). Findings suggest that symptoms evolved in the observed populations receiving the medicine, and research has explored patterns related to greater changes in certain daytime symptoms when used alongside oral antihistamines.

---

Long-Term Studies and Follow-up Consistency

The evidence base includes trials that have evaluated the medicine over short-term (e.g., 4 to 12 weeks) and intermediate-term periods (up to a year). The long-term data regarding observed patterns over periods much longer than one year are not fully established by continuous RCT data. Follow-up durations were limited in specific areas.

---

Evidence in Specific Age Groups and Subgroups

The medicine was evaluated in both pediatric patients and adults, and results apply only to the populations studied. Research has explored the use in children with asthma, where the findings describe patterns related to outcome axes that were also observed in adult populations. Research has also examined specific patient groups, such as those with asthma who also have allergic rhinitis or aspirin sensitivity.

---

Research Gaps and Areas of Uncertainty

This section synthesizes the main evidence gaps and areas where research is still developing. Comparative evidence against inhaled corticosteroids shows findings were mixed, meaning certainty remains low on specific comparative outcomes. Data for certain groups remain insufficient, particularly regarding the EIB pattern of effect for children under the age of six. Comparative evidence exploring outcomes related to nasal congestion when compared to intranasal corticosteroids is lacking.

Key Studies & References

1. Label: MONTELUKAST tablet, film coated - DailyMed (Authoritative Regulatory Information)

Common questions about Kast (FAQ)

Q: Is Kast a steroid or an anti-inflammatory medicine?

Kast is classified as a Leukotriene Receptor Antagonist (LTRA). This means it works by blocking the effects of inflammatory mediators in the body called leukotrienes. By stopping these signals, the medicine helps to manage airway inflammation, though it is not a steroid.

---

Q: What are the general expectations for improvement while taking Kast?

Clinical studies track improvement by measuring physical outcomes like lung function, as well as patient-reported symptoms. The overall purpose of the medicine is to help maintain consistent breathing capacity and mitigate the chronic reactive state of the airways. It is designed to establish foundational, sustained control over inflammatory conditions.

---

Q: Does Kast affect liver function or require regular blood monitoring?

Official prescribing information notes that elevated liver enzymes and rare cases of liver injury (hepatitis) have been reported as adverse reactions. While the medicine carries this risk, the label itself does not make an explicit general recommendation regarding the need for routine blood monitoring. The official label advises that symptoms of liver injury have occurred in patients treated with the medicine.

---

Q: What are the signs of a serious, but rare, side effect from Kast?

The medicine carries a serious Boxed Warning regarding potential neuropsychiatric events. Regulatory warnings advise that patients and caregivers be alert for changes in behavior, agitation, depression, or suicidal thoughts. Other rare but serious reactions include systemic eosinophilia consistent with Churg-Strauss syndrome (a form of vasculitis).

---

Q: Are there any specific foods that are known to interact with Kast?

For the oral granule form specifically, official documents note that a high-fat meal reduces the maximum amount of medicine absorbed into the body. Conversely, the film-coated tablets can be administered with or without food, as noted in the documentation.

---

Q: Is it true that Kast can affect the quality of sleep?

Yes, official prescribing information lists sleep disturbances as one of the neuropsychiatric events reported in association with the medicine. Other related reactions noted include nightmares and insomnia.

---

Q: Is Kast considered a 'first-line' treatment option?

Official documents state that for the treatment of allergic rhinitis, use is often reserved for patients who have not responded adequately to other treatments. For chronic asthma, the status is based on the benefits and risks for the individual patient.

---

Q: Are headaches a common side effect reported with Kast?

Yes, headache has been reported as a frequently occurring adverse experience in post-marketing reports, according to official safety documentation.

---

Q: Is there a risk of long-term kidney problems associated with Kast use?

Official information indicates that the medicine is primarily cleared from the body through bile, not urine. Due to this excretion profile, the product label states that no dosage adjustment is typically recommended for patients with renal impairment.

---

Q: Does Kast have known interactions with common over-the-counter pain relievers?

Official interaction studies have not documented significant interactions with common everyday painkillers. However, official information advises caution if non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen have caused asthma symptoms to worsen in the past.

---

Q: Can Kast interact with vitamins, herbs, or dietary supplements?

Official regulators state there is not enough information to definitively establish documented interactions with complementary medicines and herbal remedies. This is because these products are not tested for their effect on the medicine in the same rigorous way as prescription drugs.

---

Q: Is it necessary to avoid alcohol completely while taking Kast?

The regulatory label does not document a specific interaction between this medicine and alcohol. However, official labeling notes that both alcohol consumption and this medicine are associated with risks to the liver, including rare cases of liver injury.

---

Q: Are there documented interactions between Kast and oral contraceptives?

Clinical studies have specifically examined this combination. The official documents state that the medicine did not show clinically significant interactions when co-administered with oral contraceptives.

---

Q: Can older adults safely use Kast?

Official information states that no dosage adjustment is recommended for the elderly population. The results from clinical studies have not revealed geriatric-specific problems that would require altering the dosage.

---

Q: Are there special considerations for people with a history of heart problems taking Kast?

Palpitations (a fluttering or pounding heart) are listed as a post-marketing adverse reaction. Additionally, the official label requires physicians to be alert to potential cardiac complications in patients with eosinophilic conditions.

---

Q: Is there a lot of long-term safety data available on Kast?

The official evidence base includes data from trials lasting up to a year. However, regulatory documents indicate that long-term data regarding observed patterns over periods much longer than one year are not fully established by continuous controlled trials.

---

Q: How does the brand name Kast compare to its generic version, if one exists?

The active ingredient in Kast is montelukast sodium, which is available as a generic. Official safety warnings, including the serious Boxed Warning regarding neuropsychiatric events, apply equally to all formulations, covering both the brand-name medicine and the generic product.

---

Q: Is it common to feel tired or fatigued when first starting Kast?

Fatigue (feeling tired) is listed as a less common side effect, and drowsiness is classified as an uncommon side effect. Somnolence (sleepiness) has also been reported in cases of acute overdose.

---

Q: What should be done if someone accidentally takes more Kast than prescribed?

Official prescribing information notes that there is no specific treatment available for an overdose of the medicine. In the event of an overdose, official documents advise that standard supportive measures and clinical monitoring by a healthcare professional may be used.

---

Q: Does Kast have any known interactions with vaccines?

Official guidance indicates that medicines like Kast generally do not interfere with vaccines. Regulatory-aligned guidance states that the medicine is generally not known to interfere with vaccine efficacy.

How to Store and Dispose of Kast?

Official regulatory labeling dictates strict conditions for storing and disposing of Kast (Montelukast sodium) to maintain product stability.

Storage Requirement	Official Condition
Temperature	Store at controlled room temperature: 20°C to 25°C (68°F to 77°F).
Protection	Must be protected from moisture and light; keep in the original, tightly closed container.
Child Safety	Keep out of the sight and reach of children.
Granule Stability	Oral granules must be used within 15 minutes of opening the sachet.

For disposal, the regulatory instruction is to not discard unused or expired medicine into household waste or wastewater (e.g., flushing). Unneeded medication should be disposed of by consulting a pharmacist for appropriate pharmaceutical waste procedures.